PHP76 Evidence Requirements for Pricing and Reimbursement Decision Making for Orphan Drugs in Asia

Abstract

years). Seven out of the 9 patient were under the care of at least two physicians. Dyslipidemia, hypertension and diabetes are the main condition affecting the participants (100%, 88.9%, 66.7%, respectively). A total of 12 DRP were detected: underuse of medication (nϭ7, of which 2 were due to non-compliance), overuse of medication (nϭ1), incorrect timing (nϭ2) and therapy failure (nϭ2). Pharmacists spent an average 3.5 hours per home visit. Total programme cost was $787.5 (9 visits x $25/hr x 3.5hr/ visit). Hence, cost per DRP detected was estimated at $65.63. One of the DRP detected was vertigo without treatment. Hence, programme cost may be potentially offset by the savings from avoiding an episode of hospitalization due to fall. CONCLUSIONS: DRP is prevalent and potentially preventable but were undetected in this primary care sample. Hence, there is a role for HBMR. We are currently conducting a longitudinal randomized controlled trial to evaluate the cost-effectiveness of providing and not providing HBMR by collecting direct and indirect costs, health services utilization and health-related quality of life outcomes at baseline and 6-months.